Health & Fitness
Health and Fitness
Health and Fitness
Mon, January 12, 2009
Covalon Technologies Ltd.: Covalon Welcomes New Board Member
MISSISSAUGA, ONTARIO--(Marketwire - Jan. 12, 2009) - Covalon Technologies Ltd. (the "Corporation" or "Covalon") (TSX VENTURE:COV) announces today that Mr. David McFaul has joined its Board of Directors.
Mr. McFaul is currently Senior Vice-President of International at Boston Scientific Corporation, a world leader in cardiovascular medical products. He has worked at Boston Scientific since 1995 and held numerous leadership positions in various international markets.
Brad Williams, Chairman of the Board, commented: "David McFaul is a results oriented executive with extensive experience in sales, marketing, and product development with major medical device companies who are leaders in their field. I worked with David for seven years when I was the head of Stryker Corporation's Canadian Division, and he was instrumental in helping us build a world class team that led the field in the markets in which we competed. His experience in the medical device industry and his proven track record of success positions him well to help Covalon as it enters its next phase of growth."
Dr. Frank DiCosmo, President & CEO, said: "David adds valuable expertise to Covalon's Board. Prior to his current role at Boston Scientific Corporation, he served as Regional President of Asia-Pacific & Japan operations. David was also Vice President of Sales, Inter-Continental, responsible for overall sales execution for the business. The role included training and developing more than 400 sales representatives and 85 sales managers in 35 countries. David brings tremendous experience to Covalon, having been involved in high-performance sales management programs as well as clinical training programs. David has also served as Vice President and General Manager in Latin America, Canada and South Africa where he increased revenue by almost 50%. He was also General Manager, Canada and South Africa, Country Manager of Canada and National Sales Manager, Canada. I first met David almost 10 years ago, and I am very pleased to now welcome David to Covalon's Board of Directors."
Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. Management assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release, and has neither approved nor disapproved of the contents of this release.
